Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]About diabetes. World Health Organization. (2014)

  • [2]Shi Y, Hu FB: The global implications of diabetes and cancer. Lancet 383 (9933):1947-8 (2014)

  • [3]Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M, et al: Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380 (9859):2163-96 (2012)

  • [4]The top 10 causes of death Fact sheet N°310. World Health Organization. (2013)

  • [5]Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN: Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32(7):1335-43 (2009)

  • [6]Diabetes Fact sheet N°312. World Health Organization. (2013)

  • [7]Emerging Risk Factors Collaboration1, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al: Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375 (9733):2215-22 (2010)

  • [8]O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al: 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 127(4):e362-425 (2013)

  • [9]Danaei G, Lawes CM, Vander Hoorn S, Murray CJ, Ezzati M: Global and regional mortality from ischaemic heart disease and stroke attributable to higher-than-optimum blood glucose concentration: comparative risk assessment. Lancet 368 (9548):1651-9 (2006)

  • [10]Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, et al: Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56(7):1761-72 (2007)

  • [11]Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC: The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci U S A 105(39):15064-9 (2008)

  • [12]Wells JM, Rossi O, Meijerink M, van Baarlen P: Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci U S A 108 Suppl 1:4607-14 (2011)

  • [13]Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, etal: Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5(2):e9085 (2010)

  • [14]Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM: Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50(11):2374-83 (2007)

  • [15]Chiang JL, Kirkman MS, Laffel LM, Peters AL; Type 1 Diabetes Sourcebook Authors: Type 1 diabetes through the life span: a position statement of the American Diabetes Association. Diabetes Care 37(7):2034-54 (2014)

  • [16]Hara N, Alkanani AK, Ir D, Robertson CE, Wagner BD, Frank DN, Zipris D: Prevention of virus-induced type 1 diabetes with antibiotic therapy. J Immunol 189(8):3805-14 (2012)

  • [17]Mejía-León ME, Petrosino JF, Ajami NJ, Domínguez-Bello MG, de la Barca AM: Fecal microbiota imbalance in Mexican children with type 1 diabetes. Sci Rep 4:3814 (2014)

  • [18]Soyucen E, Gulcan A, Aktuglu-Zeybek AC, Onal H, Kiykim E, Aydin A: Differences in the gut microbiota of healthy children and those with type 1 diabetes. Pediatr Int 56(3):336-43 (2014)

  • [19]Hansen CH, Krych L, Nielsen DS, Vogensen FK, Hansen LH, Sørensen SJ, Buschard K, Hansen AK: Early life treatment with vancomycin propagates Akkermansia muciniphila and reduces diabetes incidence in the NOD mouse. Diabetologia 55(8):2285-94 (2012)

  • [20]Alam C, Bittoun E, Bhagwat D, Valkonen S, Saari A, Jaakkola U, et al: Effects of a germ-free environment on gut immune regulation and diabetes progression in non-obese diabetic (NOD) mice. Diabetologia 54(6):1398-406 (2011)

  • [21]Kriegel MA, Sefik E, Hill JA, Wu HJ, Benoist C, Mathis D: Naturally transmitted segmented filamentous bacteria segregate with diabetes protection in nonobese diabetic mice. Proc Natl Acad Sci U S A 108(28):11548-53 (2011)

  • [22]Wang X, Ota N, Manzanillo P, Kates L, Zavala-Solorio J, Eidenschenk C: Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature 514 (7521):237-41 (2014)

  • [23]Visser JT, Bos NA, Harthoorn LF, Stellaard F, Beijer-Liefers S, Rozing J, van Tol EA: Potential mechanisms explaining why hydrolyzed casein-based diets outclass single amino acid-based diets in the prevention of autoimmune diabetes in diabetes-prone BB rats. Diabetes Metab Res Rev 28(6):505-13 (2012)

  • [24]Patrick C, Wang GS, Lefebvre DE, Crookshank JA, Sonier B, Eberhard C, et al: Promotion of autoimmune diabetes by cereal diet in the presence or absence of microbes associated with gut immune activation, regulatory imbalance, and altered cathelicidin antimicrobial Peptide. Diabetes 62(6):2036-47 (2013)

  • [25]Hansen CH, Krych L, Buschard K, Metzdorff SB, Nellemann C, Hansen LH, et al: A Maternal Gluten-Free Diet Reduces Inflammation and Diabetes Incidence in the Offspring of NOD Mice. Diabetes 63(8):2821-32 (2014)

  • [26]Peng J, Narasimhan S, Marchesi JR, Benson A, Wong FS, Wen L: Long term effect of gut microbiota transfer on diabetes development. J Autoimmun pii: S0896-8411(14)00069-9 (2014)

  • [27]Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R: Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57(6):1470-81 (2008)

  • [28]Larsen N, Vogensen FK, van den Berg FW, Nielsen DS, Andreasen AS, Pedersen BK, etal: Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5(2):e9085 (2010)

  • [29]Wu X, Ma C, Han L, Nawaz M, Gao F, Zhang X, et al: Molecular characterisation of the faecal microbiota in patients with type II diabetes. Curr Microbiol 61(1):69-78 (2010)

  • [30]Sato J, Kanazawa A, Ikeda F, Yoshihara T, Goto H, Abe H, et al: Gut dysbiosis and detection of “live gut bacteria” in blood of Japanese patients with type 2 diabetes. Diabetes Care 37(8):2343-50 (2014)

  • [31]King C, Sarvetnick N: The incidence of type-1 diabetes in NOD mice is modulated by restricted flora not germ-free conditions. PLoS One 6(2):e17049 (2011)

  • [32]Reid G, Sanders ME, Gaskins HR, Gibson GR, Mercenier A, Rastall R, Roberfroid M, Rowland I, Cherbut C, Klaenhammer TR: New scientific paradigms for probiotics and prebiotics. J Clin Gastroenterol 37:105-118 (2003)

  • [33]Gill H, Prasad J: Probiotics, immunomodulation, and health benefits. Adv Exp Med Biol 606:423-54 (2008)

  • [34]Food and Agriculture Organization of the United Nations, World Health Organization. Probiotics in food: health and nutritional properties and guidelines for evaluation. Rome: Food and Agriculture Organization of the United Nations, World Health Organization (2006)

  • [35]Kingma SD, Li N, Sun F, Valladares RB, Neu J, Lorca GL: Lactobacillus johnsonii N6.2. stimulates the innate immune response through Toll-like receptor 9 in Caco-2 cells and increases intestinal crypt Paneth cell number in biobreeding diabetes-prone rats. J Nutr 141(6):1023-8 (2011)

  • [36]Kondrashova A, Hyöty H: Role of viruses and other microbes in the pathogenesis of type 1 diabetes. Int Rev Immunol 33(4):284-95 (2014)

  • [37]Lai KK, Lorca GL, Gonzalez CF: Biochemical properties of two cinnamoyl esterases purified from a Lactobacillus johnsonii strain isolated from stool samples of diabetes-resistant rats. Appl Environ Microbiol 75(15):5018-24 (2009)

  • [38]Valladares R, Sankar D, Li N, Williams E, Lai KK, Abdelgeliel AS, et al: Lactobacillus johnsonii N6.2. mitigates the development of type 1 diabetes in BB-DP rats. PLoS One 5(5):e10507 (2010)

  • [39]Shao F, Yang CG, Liu X, Yang DG: Application of microbiological and immunological enteral nutrition in patients with gastrointestinal cancer complicated with diabetes mellitus. Zhonghua Wei Chang Wai Ke Za Zhi 15(5):476-9 (2012)

  • [40]Mazloom Z, Yousefinejad A, Dabbaghmanesh MH: Effect of probiotics on lipid profile, glycemic control, insulin action, oxidative stress, and inflammatory markers in patients with type 2 diabetes: a clinical trial. Iran J Med Sci 38(1):38-43 (2013)

  • [41]Alokail MS, Sabico S, Al-Saleh Y, Al-Daghri NM, Alkharfy KM, Vanhoutte PM, McTernan PG: Effects of probiotics in patients with diabetes mellitus type 2: study protocol for a randomized, double-blind, placebo-controlled trial. Trials 14:195 (2013)

  • [42]Fallucca F, Porrata C, Fallucca S, Pianesi M: Influence of diet on gut microbiota, inflammation and type 2 diabetes mellitus. First experience with macrobiotic Ma-Pi 2 diet. Diabetes Metab Res Rev 30 Suppl 1:48-54 (2014)

  • [43]Thomas DW, Greer FR: Probiotics and prebiotics in pediatrics. Pediatrics 126:1217-1231 (2010)

  • [44]Quigley EM: Prebiotics and probiotics: their role in the management of gastrointestinal disorders in adults. Nutr Clin Pract 27:195-200 (2012)

  • [45]Barengolts E: Vitamin D and Prebiotics May Benefit the Intestinal Microbacteria and Improve Glucose Homeostasis in Prediabetes and Type 2 Diabetes. Endocr Pract 1-40 (2013)

  • [46]Kellow NJ, Coughlan MT, Savige GS, Reid CM: Effect of dietary prebiotic supplementation on advanced glycation, insulin resistance and inflammatory biomarkers in adults with pre-diabetes: a study protocol for a double-blind placebo-controlled randomised crossover clinical trial. BMC Endocr Disord 14:55 (2014)

  • [47]Wen L, Ley RE, Volchkov PY, Stranges PB, Avanesyan L, Stonebraker AC, et al: Innate immunity and intestinal microbiota in the development of Type1 diabetes. Nature 455 (7216):1109-13 (2008)

  • [48]Remely M, Aumueller E, Merold C, Dworzak S, Hippe B, Zanner J, et al: Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene 537(1):85-92 (2014)

  • [49]Remely M, Aumueller E, Jahn D, Hippe B, Brath H, Haslberger AG: Microbiota and epigenetic regulation of inflammatory mediators in type 2 diabetes and obesity. Benef Microbes 5(1):33-43 (2014)

  • [50]Bird A: Perceptions of epigenetics. Nature 447 (7143):396-8 (2007)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2016Review
Gut microbiota and immunopathogenesis of diabetes mellitus type 1 and 2
Fei Wang 1, Chunfang Zhang 2, Qiang Zeng 1,*
Affiliations
Article Info

1 Health Management Institute, Chinese PLA General Hospital, Beijing 100853, China

2 Clinical Epidemiology and Biostatistics, Peking University People’s Hospital, Beijing 100044, China

Abstract

Diabetes mellitus (DM) is a major increasing global health burden in the aging population. Understanding the etiology of DM is beneficial for its prevention as well as treatment. In light of the metagenome hypothesis, defined as the overall bacterial genome, gut microbes have attracted increasing attention in the pathogenesis of DM. Many studies have found that gut microbes are involved in the immunopathogenesis of DM. Probiotics strengthen the host’s intestinal barrier and modulate the immune system, and have therefore been investigated in DM management. Recent epigenetic findings in context of genes associated with inflammation suggest a possible way in which gut microbiota participate in the immunopathogenesis of DM. In this review, we discuss the role of gut microbiota in the immunopathogenesis of DM.

Keywords

  • Diabetes mellitus
  • Gut microbiota
  • Treg
  • Review

References